通过在细胞质中保留HIF-α,IRF3减弱了缺氧信号
Hongyan Deng1, Shuke Jia2, Chunchun Zhu3
1State Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Hubei Hongshan Laboratory, Wuhan, P.R. China; College of Life Science, Wuhan University, Wuhan 430072, P.R. China.
Cell reports
|January 11, 2026
概括
静止细胞质干扰素调节因子3 (IRF3) 结合缺氧诱导因子 (HIF),防止缺氧信号传递. 破坏IRF3会增强缺氧反应和耐受性,这揭示了IRF3在调节细胞对低氧反应中的新作用.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 分子生物学分子生物学
背景情况:
- 干扰素调节因子3 (IRF3) 对于先天的抗病毒免疫力至关重要,主要在核定位时作为转录因子.
- 细胞质IRF3在非传染状态中的作用,特别是它与其他信号通路的相互作用,尚不清楚.
研究的目的:
- 在没有病毒感染的情况下,研究细胞质干扰素调节因子3 (IRF3) 的功能.
- 为了确定IRF3是否与低氧信号通路相互作用和调节.
主要方法:
- 同免疫沉测试检测蛋白质与蛋白质相互作用.
- 对低氧反应元素的基因表达的分析.
- 在低氧条件下对IRF3缺乏的小鼠和斑马鱼进行表型分析.
主要成果:
- 静止的细胞质IRF3直接与低氧诱导因子-1α (HIF-1α) 和HIF-2α相互作用.
- 这种相互作用在细胞质中隔离HIF-α蛋白,抑制它们的转录活性并减弱缺氧信号.
- 在体内IRF3缺乏导致高调低氧反应基因和对低氧压力的耐受性增加.
结论:
- 细胞质IRF3通过在细胞质中保留HIF-α,在非传染性条件下作为低氧信号的负调节器.
- IRF3在调节细胞适应缺氧方面发挥着重要作用,独立于其已知的抗病毒功能.
- 这些发现揭示了免疫系统和缺氧反应途径之间的新交叉声.
更多相关视频
相关概念视频
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Regulation of the Unfolded Protein Response
2.9K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.9K
Hypoxia
1.9K
Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
1.9K
TGF - β Signaling Pathway
10.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K


